Loading…
Mahamaya Lifesciences (BSE 544611)₹178.05−3.70%Pesticides & Agrochemicals
In the Mar 2026 quarter (consolidated), Mahamaya Lifesciences reported sales of ₹166 Cr and net profit of ₹7.98 Cr. For the year to Mar 2026, sales were ₹330 Cr and net profit ₹16.95 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Sep 2024 | Sep 2025 | Mar 2026 | |
|---|---|---|---|
| Sales | 146 | 164 | 166 |
| Expenses | 133 | 148 | 149 |
| Operating Profit | 12.98 | 14.97 | 16.96 |
| OPM % | 9.0% | 9.0% | 10.0% |
| Other Income | 0.99 | 0.99 | 0.99 |
| Interest | 3.99 | 3.99 | 3.99 |
| Depreciation | 0.99 | 0.99 | 0.99 |
| Profit before tax | 9.97 | 10.97 | 11.96 |
| Tax % | 27.0% | 26.9% | 34.9% |
| Net Profit | 6.97 | 7.97 | 7.98 |
| EPS (Rs) | 4.09 | 4.72 | 3.49 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales | 90.19 | 137 | 162 | 265 | 330 |
| Expenses | 83.93 | 128 | 148 | 241 | 296 |
| Operating Profit | 5.99 | 8.98 | 12.97 | 22.96 | 33.92 |
| OPM % | 7.0% | 6.0% | 8.0% | 9.0% | 10.0% |
| Other Income | 0.00 | 0.00 | 0.99 | 2.99 | 0.99 |
| Interest | 1.99 | 2.99 | 5.98 | 6.98 | 7.97 |
| Depreciation | 0.99 | 0.99 | 1.01 | 1.99 | 1.99 |
| Profit before tax | 3.98 | 4.99 | 6.98 | 16.93 | 23.93 |
| Tax % | 27.0% | 26.0% | 26.9% | 25.0% | 30.9% |
| Exceptional items | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Net Profit | 2.99 | 3.99 | 4.99 | 12.96 | 16.95 |
| EPS (Rs) | 21.83 | 30.10 | 41.85 | 7.30 | 7.07 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 1.01 | 1.01 | 1.01 | 18.06 | 23.07 |
| Reserves | 14.03 | 18.07 | 23.08 | 32.11 | 99.21 |
| Borrowings | 18.97 | 23.94 | 54.85 | 57.89 | 90.85 |
| Other Liabilities | 20.95 | 33.95 | 33.00 | 80.77 | 97.53 |
| Total Liabilities | 55.96 | 77.97 | 112 | 188 | 310 |
| Fixed Assets | 19.98 | 20.97 | 20.97 | 26.97 | 37.95 |
| CWIP | 1.99 | 1.99 | 2.99 | 3.99 | 5.99 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 33.99 | 54.01 | 87.98 | 157 | 267 |
| Inventories | 19.02 | 35.08 | 51.06 | 100 | 141 |
| Trade receivables | 8.98 | 9.98 | 27.97 | 47.91 | 70.83 |
| Cash & equivalents | 0.99 | 3.01 | 2.99 | 3.99 | 38.99 |
| Total Assets | 55.96 | 77.97 | 112 | 188 | 310 |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from operating activity | 1.99 | 0.99 | −22.95 | 0.99 | −29.90 |
| Cash from investing activity | −2.99 | −2.99 | −1.99 | −7.99 | −15.99 |
| Cash from financing activity | 1.01 | 2.01 | 24.06 | 9.03 | 81.21 |
| Net cash flow | 0.00 | 0.99 | 0.00 | 0.99 | 34.94 |
| Capex | 3.28 | 2.90 | 2.38 | 8.89 | 16.15 |
| Free cash flow | −1.01 | −2.01 | −25.06 | −8.02 | −46.09 |
| CFO / OP % | 56.1% | 24.1% | −161.9% | 12.1% | −74.9% |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor days | 37 | 25 | 64 | 67 | 78 |
| Inventory days | 92 | 108 | 136 | 166 | — |
| Days payable | 83 | 87 | 61 | 92 | — |
| Cash conversion cycle | 47 | 48 | 140 | 142 | 78 |
| Working capital days | 7 | 8 | 13 | 28 | 48 |
| ROCE % | — | 20.0% | 21.0% | 26.0% | 20.0% |
For the Mar 2026 quarter, Mahamaya Lifesciences reported sales of ₹166 Cr and net profit of ₹7.98 Cr. The operating margin was 10.0%.
Mahamaya Lifesciences' sales for the year to Mar 2026 were ₹330 Cr.
Net profit for the year to Mar 2026 was ₹16.95 Cr. Earnings per share over the same trailing period were ₹7.07.
Mahamaya Lifesciences reported borrowings of ₹90.85 Cr at Mar 2026, against cash and equivalents of ₹38.99 Cr.
Cash from operations was −₹29.90 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹46.09 Cr.